Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant
; 31(8): 1290-5, 2016 08.
Article
en En
| MEDLINE
| ID: mdl-26614268
ABSTRACT
BACKGROUND:
To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction.METHODS:
Thirty-two study subjects were enrolled in this study 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins.RESULTS:
At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance.CONCLUSIONS:
Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers. CLINICAL TRIAL REGISTRATION NUMBER NCT02511418.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Circulación Renal
/
Riñón Poliquístico Autosómico Dominante
/
Simvastatina
/
Tasa de Filtración Glomerular
/
Riñón
Tipo de estudio:
Diagnostic_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2016
Tipo del documento:
Article